摘要
目的:探究分析盐酸氨溴索联合利巴韦林在小儿支气管肺炎治疗中的效果.方法:选择2021年9月-2022年12月我院收治小儿支气管肺炎100例,随机分为对照组(常规抗感染、止咳平喘等治疗,n=50例)和研究组(对照组治疗基础上再联合盐酸氨溴索与利巴韦林,n=50例),对比两组患儿治疗效果,并观察患儿各症状消退时间与住院治疗时间,最后测定患儿治疗前后的肺功能指标(FVC、FEV1、PEF)水平.结果:研究组患儿治疗总体有效率96.00％,较对照组的高,P ＜ 0.05;研究组患儿退热、咳嗽消退、气喘消退、肺部啰
Abstract
Objective To explore and analyze the effect of ambroxol hydrochloride combined with ribavirin in the treatment of bronchopneumonia in children. Methods: A total of 100 children with bronchopneumonia admitted to our hospital from September 2021 to December 2022 were randomly divided into a control group (conventional anti-infection and antitussive and antiasthmatic treatments, n=50 cases) and a research group (control group combined with ambroxol hydrochloride and ribavirin on the basis of treatment, n=50 cases). The treatment effects of children in the two groups were compared, and the symptom resolution time and hospitalization time of children were observed. Finally, the lung function indexes (FVC, FEV1 and PEF) levels of children before and after treatment were measured. Results: The overall effective rate of treatment in treatment group was 96.00％, which was higher than that in the control group (P＜0.05). The durations of fever reduction, cough resolution, asthma resolution, and pulmonary rales resolution and hospitalization in the treatment group were (2.02±0.43), (4.15±0.64), (3.73±0.58), (5.26±0.73) and (5.83±1.15) d, respectively, which were shorter than those in the control group (P＜0.05). The levels of FVC, FEV1 and PEF in the treatment group were (85.63±7.42) L, (86.47±8.74) L and (90.52±9.15) L/min, respectively, which were higher than those in the control group (P＜0.05). Conclusion: The combined use of ambroxol hydrochloride and ribavirin in the treatment of children with bronchopneumonia can obtain a more ideal therapeutic effect, promote the rapid resolution of clinical symptoms in children and improve the lung function of children, which is worthy of promotion.
万方数据